Standard BioTools Profit Margin

The latest profit margin for LAB is 132.62% as of June 2026. That compares with -78.12% in the prior-year period — up 269.7% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Standard BioTools's historical trend and sector peers before judging valuation or financial health.

Over the past year, LAB's profit margin moved from -78.12% to 132.62% — a 269.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Standard BioTools's valuation or profitability profile.

Against Healthcare companies, LAB currently prints 132.62% for profit margin, while the sector average sits near 13.89%. That is roughly 854.5% above the sector mean. Large gaps often invite a closer look at Standard BioTools's growth, margins, and balance sheet.

Profit Margin shows how effectively Standard BioTools converts resources into returns. At 132.62%, LAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -78.12% in the prior-year period — up 269.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LAB's profit margin (132.62%), review year-over-year change from -78.12%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.